The only FDA-approved equine PSGAG (polysulfated glycosaminoglycan) recommended for the intramuscular treatment for non-infectious degenerative joint disease (DJD) of the carpal and hock joints.

Proven to:

• Reduce inflammation
• Restore synovial joint lubrication
• Repair joint cartilage
• Reverse the disease process